Company & Sponsor Intelligence
Supernus Pharmaceuticals, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials13
Recruiting2
Completed10
Countries2
Therapeutic footprint
adhddepressionepilepsyparkinsons
Indexed studies
NCT00908349Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT06185985Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
adhd · United StatesPHASE4
adhd · United StatesPHASE4
NCT04143217Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
adhd · United StatesPHASE3
adhd · United StatesPHASE3
NCT06798896RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
NCT00918424Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects
epilepsy · United StatesAPPROVED_FOR_MARKETING
epilepsy · United StatesAPPROVED_FOR_MARKETING
NCT02618434Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
adhd · United StatesPHASE3
adhd · United StatesPHASE3
NCT03944785Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
parkinsons · United StatesCOMPLETED
parkinsons · United StatesCOMPLETED
NCT03247530Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
adhd · United StatesPHASE3
adhd · United StatesPHASE3
NCT02942017A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
depression · United StatesPHASE3
depression · United StatesPHASE3
NCT03247543Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
adhd · United StatesPHASE3
adhd · United StatesPHASE3
NCT05518578Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
NCT03156439Bioavailability, Safety, and Tolerability of BIS-001 ER
epilepsy · AustraliaPHASE1
epilepsy · AustraliaPHASE1
Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →